Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23856034 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL23856035 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL2185848 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL9094485 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL6522546 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL27705439 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| Glycerin SCHEMBL27636932 | 0.82 | LMNA (0.36) | LMNAL3MBTL1TDP1 | |
| Valeric Acid SCHEMBL27619472 | 0.82 | AKR1B1 (0.40) | AKR1B1LMNATDP1 | |
| SCHEMBL7642895 | 0.78 | LMNA (0.35) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL27905563 | 0.78 | LMNA (0.35) | AKR1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117947024-A | SiRNA sequence for effectively inhibiting expression of complement C3 factor and application thereof | 北京键凯科技股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| WO-2024078534-A1 | INTERFERING RNA FOR INHIBITING EXPRESSION OF MELANOPHILIN (MLPH) GENE, AND APPLICATION THEREOF | 北京键凯科技股份有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-117866955-A | Interference RNA for inhibiting expression of melanin avidin (MLPH) gene and application thereof | 北京键凯科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2024061356-A1 | INTERFERING RNA FOR INHIBITING TUBB2 GENE EXPRESSION AND USE THEREOF | 北京键凯科技股份有限公司 | 2024-03-28 | — | — | WO | claimed |
| WO-2024061354-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | 北京键凯科技股份有限公司 | 2024-03-28 | — | — | WO | claimed |
| WO-2024002320-A1 | INTERFERING RNA FOR INHIBITING B7-H3 GENE EXPRESSION AND USE THEREOF | 北京键凯科技股份有限公司 | 2024-01-04 | — | — | WO | claimed |
| CN-117286143-A | Interfering RNA for inhibiting TUBB2 gene expression and application thereof | 北京键凯科技股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117264955-A | Interference RNA for inhibiting TOP1 gene expression and application thereof | 北京键凯科技股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-116790594-A | Interference RNA for inhibiting B7-H3 gene expression and application thereof | 北京键凯科技股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | claimed |
| CN-101611046-A | Antiviral nucleoside analogs | BIOCRYST PHARM INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| CN-101166750-A | Furanopyrimidine compounds and thienopyrimidine compounds for therapy | BIOCRYST PHARM INC (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | AKR1B1 2473/4885LMNA 4216/4885L3MBTL1 3450/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | AKR1B1 1340/4885LMNA 1314/4885L3MBTL1 3218/4885 |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | AKR1B1 2529/4885LMNA 2472/4885L3MBTL1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.